000963 Huadong Medicine
- 33.25
- -0.05-0.15%
Huadong Medicine News
Huadong Pharmaceutical (000963.SZ): The wholly-owned subsidiary received a notice of acceptance of drug registration
Gelonghui, May 12, 丨 Huadong Pharmaceutical (000963.SZ) announced that on May 11, 2024, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as “China-US Huadong”), a wholly-owned subsidiary of the company, received the “Notice of Acceptance” (acceptance numbers: CXHS2400040, CXHS2400041) issued by the National Drug Administration (NMPA), and Meifertinib tablets (Mifertinib Tablets) were declared by China and US as the applicant for use in the epidermal growth factor receptor (EGFR) 21 Exon number L858R
Huadong Pharmaceutical (000963.SZ): Diabetes Indications have now completed the Phase III clinical study and all subjects have been enrolled. It is expected that the main endpoint data will be obtained in Q4 2024
Gelonghui, May 11 | Huadong Pharmaceutical (000963.SZ) said on the interactive platform that the company's simeglutide injection project is progressing according to plan. All subjects of the Phase III clinical study on diabetes indications have now been enrolled, and it is expected that the main endpoint data will be obtained in Q4 2024.
East China Pharmaceutical (000963.SZ): The company's industrial microbiology focuses on two major business scenarios: the application of synthetic biology technology systems and biomedical innovation and development
Gelonghui, May 11 | Huadong Pharmaceutical (000963.SZ) said on an interactive platform that the company has been deeply involved in the field of industrial microbiology for more than 40 years and has a deep industrial base and industrial transformation capabilities. The company established a subsidiary Huida Biotech in 2020 as the company's industrial microbial technology innovation platform, and acquired Nannong Dongyao in April 2023 to quickly enter the field of animal protection. The company's industrial microbiology focuses on the two major business scenarios of synthetic biology technology system application and biomedical innovation and development. It has formed a gap in the four major fields of xRNA, specialty APIs & intermediates, health & biomaterials, and animal health
Huadong Medicine Co., Ltd's (SZSE:000963) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Huadong Medicine (SZSE:000963) has had a great run on the share market with its stock up by a significant 8.9% over the last month. As most would know, fundamentals are what usually guide market pri
Huadong Pharmaceutical (000963.SZ)'s net profit in the first quarter increased by 14.18% to 862 million yuan. The overall operations of the core subsidiaries in China and the US continued to maintain a steady growth trend
Gelonghui, April 25 | Huadong Pharmaceutical (000963.SZ) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 10.411 billion yuan, up 2.93% year on year; realized net profit of 862 million yuan, up 14.18% year on year; realized net profit to mother after deducting non-recurring profit and loss of 838 million yuan, an increase of 10.66% year on year; both operating income and net profit achieved positive growth over the fourth quarter of 2023. For example, after deducting equity incentive expenses and profits and losses attributable to shareholders of a listed company during the reporting period, non-recurring profits and losses attributable to shareholders of a listed company can be deducted
Huadong Pharmaceutical (000963.SZ): The HDM1005 injectable drug clinical trial application declared by China and the US East China has been approved by the US FDA
Gelonghui, April 22丨Huadong Pharmaceutical (000963.SZ) announced that recently, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong”), a wholly-owned subsidiary of Huadong Pharmaceutical Co., Ltd., received a notice from the US Food and Drug Administration (“US FDA”) that the HDM1005 injectable drug clinical trial application declared by China and US East China has been approved by the US FDA to conduct phase I clinical trials in the US. HDM1005 injection is a new class 1 chemical drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. and has global intellectual property rights. It is a polypeptide human GLP-1 (pancreatic hypertensive)
Huadong Pharmaceutical (000963.SZ): Hubei Meiqi factory plans to start production of 5 products in 2024
Gelonghui, April 19丨Huadong Pharmaceutical (000963.SZ) held a 2023 annual performance exchange meeting on April 18, 2024 to discuss “the industrial and micro sector, prospects for Meiqi Health to start production in 2024?” The company replied that in 2024, the Hubei Meiqi factory plans to put into operation 5 products, lay out the fields of bone health, brain health, anti-oxidation, etc., and complete system certification and international certification. After the product is put into production, it will be quickly introduced to the market through various marketing methods such as exhibitions, visits, and online channels. At the same time, fully combine shareholders' sales resources to promote strategic cooperation with key domestic and foreign customers to meet customized needs
East China Pharmaceutical (000963.SZ): Autoimmunity involves many diseases. The company is currently paying more attention to rheumatism and skin medication
Gelonghui, April 19丨Huadong Pharmaceutical (000963.SZ) held the 2023 annual performance exchange meeting on April 18, 2024. Regarding “At present, the company has achieved full coverage of small oral molecules, biopharmaceuticals and topical dosage forms in the field of self-immunity. What are the highlights of the company's indication layout in the field of self-immunity for the next 2-3 years?” The company replied that autoimmunity involves many diseases. Currently, the company is paying more attention to rheumatism and skin medications, including ARCALYST, QX001S, PRV-3279, ZORYVE cream and foam, and Wynzora? Cream etc. are included, so
Huadong Pharmaceutical (000963.SZ): Currently, initial efficacy signals of liver fat imaging have been observed in the Ib/IIA clinical trial in New Zealand
Gelonghui, April 19丨Huadong Pharmaceutical (000963.SZ) held a 2023 annual performance exchange meeting on April 18, 2024 to discuss “the future of the company's three-target GLP-1 products in NASH and weight loss?” The company replied that DR10624 is a three-target agonist targeting FGF21R/GCGR/GLP-1R, and the company will prioritize clinical research on metabolic diseases such as hypertriglyceridemia and NASH in the future. Currently, initial signs of efficacy in liver fat imaging have been observed in the Ib/IIa clinical trial in New Zealand, which is expected to bring new results to patients with metabolic diseases in the future
2024 Financial Report | After breaking through 40 billion dollars in revenue, how can Huadong Pharmaceutical face the challenge of “deceleration”
Big dividends
Huadong Medicine's 2023 Profit Jumps 14%
Huadong Medicine's (SHE:000963) attributable profit rose 14% to 2.84 billion yuan in 2023 from 2.50 billion yuan in 2022, according to a Thursday filing with the Shenzhen bourse. Earnings per share at
Returns On Capital Signal Tricky Times Ahead For Huadong Medicine (SZSE:000963)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see a company investing more capital into its business and ideally the returns earn
Huadong Pharmaceutical (000963.SZ): Somituximab injection obtained drug clinical trial approval notice
Gelonghui, April 7 | Huadong Pharmaceutical (000963.SZ) announced that its wholly-owned subsidiary Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. Somituximab injection (ELA HERE, mirvetuximab injection) was developed by China and US partner Immunogen, Inc. (“ImmunoGen”) in cooperation with US partner Immunogen, Inc. (“ImmunoGen”) IMGN853 HDM2002 ) Clinical trial application approved
Shen Wan Hongyuan: The beauty market has entered a stage of steady development and is optimistic about the market space and performance transformation of key domestic brands
China's beauty market has left a decade of rapid growth and has entered a stage of steady development.
Zheshang Securities: An important new business format that is currently breaking the pharmaceutical market, the future of the CSO sector may support the growth of relevant industry targets, etc.
The Zhitong Finance App learned that Zheshang Securities released a research report stating that profitability is related to product IP ownership, product development stage, and CSO's empowerment of products. In the future, the profitability of the CSO business is expected to continue to improve as the product structure gradually matures and the proportion of its own IP products increases. At this stage, based on judging the current macroeconomic environment and the direction of continuous deepening of medical reform, the CSO sector is an important new business format for breaking the current pharmaceutical market. Changes in business trends may support the growth and profitability of the internal standards of the business format to exceed market expectations. Recommended attention: It has proven its own brand marketing capabilities, and has mature sales channels and capabilities
Fewer Investors Than Expected Jumping On Huadong Medicine Co., Ltd (SZSE:000963)
Huadong Medicine Co., Ltd's (SZSE:000963) price-to-earnings (or "P/E") ratio of 20.1x might make it look like a buy right now compared to the market in China, where around half of the companies have P
East China Pharmaceutical (000963.SZ): ELAHERE, an ADC drug for platinum-resistant ovarian cancer, has been fully approved by the FDA
Huadong Pharmaceutical (000963.SZ) issued an announcement. Recently, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company...
Quanxin Bio-B (02509.HK) is expected to go public on March 20 and introduce Huadong Pharmaceutical as the cornerstone
Gelonghui, March 12, 丨 Quanxin Bio-B (02509.HK) announced that the company plans to sell 1.2 million shares globally, 1.2 million shares in Hong Kong, China, and 10.8416 million shares; from March 12 to March 15, 2024, the expected pricing date will be March 18; the offering price will be HK$19.80-20.20 per share, with 200 shares per lot; CICC is the sole sponsor; it is expected that the shares will be listed on the main board of the Stock Exchange on March 20, 2024. Founded in 2015, the company is
IPO Announcement | Biotech company Quanxin Bio-B (02509) will now offer shares of Jianxin Pharmaceutical and Huadong Pharmaceutical (000963.SZ) to purchase 25 million US dollars of shares
The global sale of 1,046,400 H shares, the Hong Kong public sale accounts for about 10%, and the international sale accounts for about 90%. The issue price is HK$19.8-20.2 per share, with 200 shares per lot. It is expected that H shares will start trading on the Stock Exchange at 9:00 a.m. (Hong Kong time) on March 20, 2024.
Huadong Pharmaceutical (000963.SZ) Wholly-owned Subsidiary Receives Drug Clinical Trial Approval Notice
Zhitong Finance App News, Huadong Pharmaceutical (000963.SZ) announced that Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“China-US Huadong” for short), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved by the National Drug Administration (NMPA). The HDM1005 injection clinical trial application submitted by China and the US East China was approved, agreeing to carry out clinical trials for type 2 diabetes and weight control indications.
Analysis
Price Target
No Data
